Alessandra Luchini - Fairfax VA, US Lance Liotta - Bethesda MD, US Emanuel Petricoin - Gainesville VA, US Barney Bishop - Annandale VA, US Caterina Longo - Fairfax VA, US Virginia Espina - Rockville MD, US Alexis Patanarut - Burke VA, US
International Classification:
G01N 33/545
US Classification:
436531, 42840224, 428407, 435 61, 436534, 436535
Abstract:
Capture particles for harvesting analytes from solution and methods for using them are described. The capture particles are made up of a polymeric matrix having pore size that allows for the analytes to enter the capture particles. The pore size of the capture particles are changeable upon application of a stimulus to the particles, allowing the pore size of the particles to be changed so that analytes of interest remain sequestered inside the particles. The polymeric matrix of the capture particles are made of co-polymeric materials having a structural monomer and an affinity monomer, the affinity monomer having properties that attract the analyte to the capture particle. The capture particles may be used to isolate and identify analytes present in a mixture. They may also be used to protect analytes which are typically subject to degradation upon harvesting and to concentrate low an analyte in low abundance in a fluid.
This invention relates, e. g. , to a method for predicting a subject's response to a chemotherapeutic agent and/or the subject's prognosis, comprising measuring the phosphorylation state of at least one member of the mTOR pathway, and/or of at least one member of an interconnected polypeptide pathway (e. g. a member of the Akt pathway or a member of the IRS pathway), compared to a baseline value, in a cancer tissue or cancer cell sample from the subject, wherein an elevated level of the phosphorylation state compared to the baseline value indicates that the subject is a non-responder to the chemotherapeutic agent and/or has a poor prognosis. Also described is a method for treating a cancer in a subject in need thereof, wherein the subject exhibits an elevated level of the phosphorylation state, comprising administering one or more inhibitors of the mTOR and/or an interconnected pathway.
Lance Liotta - Bethesda MD, US Weidong Zhou - Manassas VA, US Virginia Espina - Rockville MD, US Emanuel Petricoin - Gainesville VA, US
International Classification:
G01N 33/53 C12Q 1/48 G06F 19/00 A61M 31/00
US Classification:
435007100, 435015000, 604500000, 702019000
Abstract:
The present invention relates to the analysis and monitoring of ocular fluids for determining the physiological state of an organism, to monitor drug efficacy and dynamics, for early disease detection, as well as to certain molecular markers and fingerprints of identified molecules or molecule fragments in such analysis.
Inhibition Of Brain Enzymes Involved In Cerebral Amyloid Angiopathy And Macular Degeneration
Wolff Kirsch - Redlands CA, US Lance A. Liotta - Bethesda MD, US William Van Nostrand - East Setauket NY, US Harry V. Vinters - Venice CA, US Virginia A. Espina - Rockville MD, US
Assignee:
LOMA LINDA UNIVERSITY MEDICAL CENTER - Loma Linda CA GEORGE MASON UNIVERSITY - Arlington VA STONY BROOK UNIVERSITY - Stony Brook CA THE REGENTS OF THE UNIVERSITY OF CALIFORNIA - Los Angeles CA
International Classification:
A61K 31/7105 A61P 25/28
US Classification:
514 44
Abstract:
A method of treating or inhibiting progress of dementia and/or macular degeneration in a mammal involves administering compositions containing siRNA to heme oxygenase-1 (HO-1) or heme oxygenase-2 (HO-2), a matrix metalloproteinase (MMP) inhibitor, a caspase inhibitor, or a metalloporphyrin in a manner that permits access to brain sites and/or the macula of the patient.
Inhibition Of Brain Enzymes Involved In Cerebral Amyloid Angiopathy And Macular Degeneration
Wolff Kirsch - Redlands CA, US Lance A. Liotta - Bethesda MD, US William Van Nostrand - East Setauket NY, US Harry V. Vinters - Venice CA, US Virginia A. Espina - Rockville MD, US
Assignee:
LOMA LINDA UNIVERSITY MEDICAL CENTER - Loma Linda CA GEORGE MASON UNIVERSITY - Arlington VA STONY BROOK UNIVERSITY - Stony Brook CA THE REGENTS OF THE UNIVERSITY OF CALIFORNIA - Los Angeles CA
International Classification:
A61K 9/127 A61K 31/7052 A61K 31/555 A61P 25/28
US Classification:
424450, 514 44 A, 514185
Abstract:
A method of treating or inhibiting progress of dementia and/or macular degeneration in a mammal involves administering compositions containing siRNA to heme oxygenase-1 (HO-1) or heme oxygenase-2 (HO-2), a matrix metalloproteinase (MMP) inhibitor, a caspase inhibitor, or a metalloporphyrin in a manner that permits access to brain sites and/or the macula of the patient.
Lance A. Liotta - Bethesda MD, US David Geho - Oakton VA, US Virginia A. Espina - Rockville MD, US
Assignee:
George Mason Intellectual Properties, Inc. - Fairfax VA
International Classification:
A01N 1/02 G01N 33/48 C07K 14/00 C12M 1/00
US Classification:
435 11, 435 405, 530402, 4352841
Abstract:
This invention relates, e.g., to a composition that, at room temperature, when contacted with a sample comprising phosphoproteins, can fix and stabilize cellular phosphoproteins, preserve cellular morphology, and allow the sample to be frozen to generate a cryostat frozen section suitable for molecular analysis. The composition comprises (1) a fixative that is effective to fix the phosphoproteins, and that has a sufficient water content to be soluble for a stabilizer and/or a permeability enhancing agent); (2) a stabilizer, comprising (a) a kinase inhibitor and (b) a phosphatase inhibitor and, optionally, (c) a protease (e.g., proteinase) inhibitor; and (3) a permeability enhancing agent (e.g. PEG). Methods are described for preserving phosphoproteins, using such a composition. Also described are endogenous surrogate markers for monitoring protein degradation, including the loss of posttranslational modifications (such as phosphorylation), e.g. the following removal of a cell or tissue from a subject; and exogenous molecular sentinels (e.g. phosphoproteins attached to magnetic nanoparticles) that allow one to evaluate the processing history of a cellular or tissue population sample.
Lance A. Liotta - Bethesda MD, US Wolff Kirsch - Redlands CA, US Virginia Espina - Rockville MD, US Emanuel Petricoin, III - Gainesville VA, US Mark Ross - Charlottesville VA, US Claudius Mueller - Loma Linda CA, US Shino Magaki - Redlands CA, US
Low molecular weight (LMW) peptides have been discovered that are indicative of neurological conditions, such as Alzheimer's Disease (AD), cognitive impairment and brain microhemmorhages. Evaluating patient samples for the presence of such LMW peptides is an effective means of detecting neurological conditions and monitoring the progression of the disease. The LMW peptides are particularly useful in detecting neurological conditions during the early stages without invasive procedures.
Post-Exposure Prophylaxis And Treatment Of Infections
Serguei G. Popov - Bristow VA, US Taissia Popov - Bristow VA, US Virginia Espina - Rockville MD, US Charles Bailey - Cross Junction VA, US Lance A. Liotta - Bethesda MD, US Emanuel Petricoin - Gainesville VA, US
Assignee:
George Mason Intellectual Properties Inc. - Fairfax VA
International Classification:
A61K 38/07 A61P 31/04
US Classification:
514 24
Abstract:
The invention provides methods and materials for identifying agents for preventing and/or treating anthrax and similar diseases. Embodiments provide strains and model systems for studying non-lethal and lethal exposure to anthrax and similar disease vectors. Embodiments provide materials and methods for using the strains and model systems for differential profiling, such as proteomic profiling, such as differentiation phosphorylation profiling, to target identification and therapeutics discovery and development. Embodiments provide pharmaceutically acceptable compositions, and methods for using them to prevent and/or treat anthrax and similar diseases comprising an agent that decreases the activity of caspase , such as YVAD, and/or an agent that increases the phosphorylation of AKT, such as IB-MECA or Cl-IB-MECA, together with, in particular embodiments, an antibiotic, such as ciprofloxacin. Kits comprising the same are provided as well, among other things.
National Institutes of Health May 2002 - May 2005
Manager, Laser Capture Microdissection Core Facility
Shady Grove Adventist Hospital Feb 2002 - May 2002
Interim Lab Director
Adventist Health Care/Shady Grove Adventist Hospital Mar 1993 - Feb 2002
Medical Technologist
George Mason University Mar 1993 - Feb 2002
Research Professor
Education:
George Mason University 2010 - 2013
Doctorates, Doctor of Philosophy, Philosophy
The Johns Hopkins University 1997 - 1999
Master of Science, Masters, Biotechnology
Rochester Institute of Technology 1978 - 1982
Bachelors, Bachelor of Science
Skills:
Proteomics Immunohistochemistry Clinical Research Western Blotting Animal Models Clinical Trials Genetics Mammalian Cell Culture Science Cell Culture Hematology Life Sciences Molecular Biology Statistics Qpcr Elisa Biochemistry Laboratory Laser Capture Microdissection Clia Reverse Phase Protein Microarray Urinalysis Biotechnology Cell Biology Genomics Microbiology Protein Chemistry Research Clinical Laboratory Management Qualitative Research Clinical Chemistry Blood Bank